Tags

Type your tag names separated by a space and hit enter

Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.
Rev Med Virol. 2021 11; 31(6):e2231.RM

Abstract

The Spike protein is the target of both antibody-based therapeutics (convalescent plasma, polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect efficacy of those treatments. Hence, monitoring of mutations is necessary to forecast and readapt the inventory of therapeutics. Different phylogenetic nomenclatures have been used for the currently circulating SARS-CoV-2 clades. The Spike protein has different hotspots of mutation and deletion, the most dangerous for immune escape being the ones within the receptor binding domain (RBD), such as K417N/T, N439K, L452R, Y453F, S477N, E484K, and N501Y. Convergent evolution has led to different combinations of mutations among different clades. In this review we focus on the main variants of concern, that is, the so-called UK (B.1.1.7), South African (B.1.351) and Brazilian (P.1) strains.

Authors+Show Affiliations

North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33724631

Citation

Focosi, Daniele, and Fabrizio Maggi. "Neutralising Antibody Escape of SARS-CoV-2 Spike Protein: Risk Assessment for Antibody-based Covid-19 Therapeutics and Vaccines." Reviews in Medical Virology, vol. 31, no. 6, 2021, pp. e2231.
Focosi D, Maggi F. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev Med Virol. 2021;31(6):e2231.
Focosi, D., & Maggi, F. (2021). Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. Reviews in Medical Virology, 31(6), e2231. https://doi.org/10.1002/rmv.2231
Focosi D, Maggi F. Neutralising Antibody Escape of SARS-CoV-2 Spike Protein: Risk Assessment for Antibody-based Covid-19 Therapeutics and Vaccines. Rev Med Virol. 2021;31(6):e2231. PubMed PMID: 33724631.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. AU - Focosi,Daniele, AU - Maggi,Fabrizio, Y1 - 2021/03/16/ PY - 2021/01/29/revised PY - 2021/01/07/received PY - 2021/02/15/accepted PY - 2021/3/17/pubmed PY - 2021/11/26/medline PY - 2021/3/16/entrez KW - B.1.1.7 KW - B.1.351 KW - BNT162b2 KW - COVID-19 KW - LY-CoV555 KW - LyCoV016 KW - P.1 KW - P.2 KW - REGN10933 KW - REGN10987 KW - SARS-CoV-2 KW - bamlanivimab KW - casirivimab KW - convalescent plasma KW - etesevimab KW - imdevimab KW - immune escape KW - mRNA-1273 KW - mutations KW - neutralising antibody KW - polyclonal immunoglobulins SP - e2231 EP - e2231 JF - Reviews in medical virology JO - Rev Med Virol VL - 31 IS - 6 N2 - The Spike protein is the target of both antibody-based therapeutics (convalescent plasma, polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect efficacy of those treatments. Hence, monitoring of mutations is necessary to forecast and readapt the inventory of therapeutics. Different phylogenetic nomenclatures have been used for the currently circulating SARS-CoV-2 clades. The Spike protein has different hotspots of mutation and deletion, the most dangerous for immune escape being the ones within the receptor binding domain (RBD), such as K417N/T, N439K, L452R, Y453F, S477N, E484K, and N501Y. Convergent evolution has led to different combinations of mutations among different clades. In this review we focus on the main variants of concern, that is, the so-called UK (B.1.1.7), South African (B.1.351) and Brazilian (P.1) strains. SN - 1099-1654 UR - https://www.unboundmedicine.com/medline/citation/33724631/Neutralising_antibody_escape_of_SARS_CoV_2_spike_protein:_Risk_assessment_for_antibody_based_Covid_19_therapeutics_and_vaccines_ L2 - https://doi.org/10.1002/rmv.2231 DB - PRIME DP - Unbound Medicine ER -